Literature DB >> 10576664

Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients.

M Kuczyk1, S Machtens, K Hradil, J Schubach, W Christian, R Knüchel, J Hartmann, C Bokemeyer, U Jonas, J Serth.   

Abstract

The p27Kip1 gene has been identified as inductor of cell cycle arrest at the G1 checkpoint to prevent entry of somatic cells into the S phase of the cell cycle when substantial DNA damage has occurred. It has been suggested that decreased expression of the p27Kip1 protein may contribute to the development of human malignancies due to loss of critical antiproliferative mechanisms. In the present study, 95 specimens (T1-T4) from 95 randomly selected patients undergoing radical prostatectomy at the Urological Department of Hannover University (82 patients) as well as in the Josef Hospital Regensburg (13 patients) between 1981 and 1992 for whom tissue blocks for immunohistochemical investigation were available, were investigated for different biological and clinical characteristics as possible predictors for recurrence-free and long-term survival: age, depth of tumour infiltration, histological grade, lymph node status, as well as decreased expression of the p27Kip1 protein. After a median follow-up up of 56 months (24-151 months), seven of 21 (33%) patients (Group 1) with loss of p27Kip1 protein expression or a relative amount of <10% of positively stained tumour cells developed recurrent disease in contrast to 17 of 74 (23%) patients (Group 2) with retained p27Kip1 protein expression (> or =10% of positively stained tumour cells). The median recurrence-free survival was 14 months (5-40 months) for patients from Group 1 and 31 months (7-133 months) for Group 2 patients (P = 0.02). In multivariate analysis, loss of p27Kip1 protein expression was identified as the only independent prognostic parameter for recurrence-free survival. In contrast, neither the univariate nor the multivariate analysis showed a correlation between loss of p27Kip1 protein expression and the long-term survival of the patients. Prospective studies are urgently needed to confirm the independent prognostic value of decreased p27Kip1 protein expression together with overexpression of the p53 tumour suppressor protein in patients with localized prostate cancer. The availability of more refined prognostically important biological variables in addition to established prognostic factors like tumour stage or Gleason score might help decision making in patients at high risk for the development of local recurrence or systemic tumour progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10576664      PMCID: PMC2362945          DOI: 10.1038/sj.bjc.6690806

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy.

Authors:  M A Kuczyk; J Serth; C Bokemeyer; S Machtens; A Minssen; W Bathke; J Hartmann; U Jonas
Journal:  Eur J Cancer       Date:  1998-04       Impact factor: 9.162

2.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

3.  High 10-year survival rate in patients with early, untreated prostatic cancer.

Authors:  J E Johansson; H O Adami; S O Andersson; R Bergström; L Holmberg; U B Krusemo
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

4.  Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals.

Authors:  K Polyak; M H Lee; H Erdjument-Bromage; A Koff; J M Roberts; P Tempst; J Massagué
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

5.  Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy.

Authors:  D A Ackerman; J M Barry; R A Wicklund; N Olson; B A Lowe
Journal:  J Urol       Date:  1993-12       Impact factor: 7.450

6.  Natural history of localised prostatic cancer managed by conservative therapy alone.

Authors:  N J George
Journal:  Lancet       Date:  1988-03-05       Impact factor: 79.321

7.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer.

Authors:  T A Stamey; F S Freiha; J E McNeal; E A Redwine; A S Whittemore; H P Schmid
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

8.  Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation.

Authors:  J Y Kato; M Matsuoka; K Polyak; J Massagué; C J Sherr
Journal:  Cell       Date:  1994-11-04       Impact factor: 41.582

9.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors.

Authors:  M V Ponce-Castañeda; M H Lee; E Latres; K Polyak; L Lacombe; K Montgomery; S Mathew; K Krauter; J Sheinfeld; J Massague
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

10.  Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer.

Authors:  F Bullrich; T K MacLachlan; N Sang; T Druck; M L Veronese; S L Allen; N Chiorazzi; A Koff; K Heubner; C M Croce
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

View more
  14 in total

Review 1.  Prognostic determinants in prostate cancer.

Authors:  Neil E Martin; Lorelei A Mucci; Massimo Loda; Ronald A Depinho
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

2.  Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays.

Authors:  Viju Ananthanarayanan; Ryan J Deaton; Anup Amatya; Virgilia Macias; Ed Luther; Andre Kajdacsy-Balla; Peter H Gann
Journal:  Hum Pathol       Date:  2011-02-02       Impact factor: 3.466

Review 3.  The AR dependent cell cycle: mechanisms and cancer relevance.

Authors:  Matthew J Schiewer; Michael A Augello; Karen E Knudsen
Journal:  Mol Cell Endocrinol       Date:  2011-07-12       Impact factor: 4.102

4.  Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies.

Authors:  Tina Dreher; Hanswalter Zentgraf; Ulrich Abel; Alexandra Kappeler; Maurice S Michel; Uwe Bleyl; Rainer Grobholz
Journal:  Virchows Arch       Date:  2004-04-29       Impact factor: 4.064

Review 5.  Molecular and genetic prognostic factors of prostate cancer.

Authors:  Arnab Chakravarti; Gary Guotang Zhai
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

6.  Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer.

Authors:  Imre Romics; Gergely Bánfi; Eszter Székely; Tibor Krenács; Béla Szende
Journal:  Pathol Oncol Res       Date:  2008-04-16       Impact factor: 3.201

7.  Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells.

Authors:  David Nikoleishvili; Ambrosi Pertia; Omar Trsintsadze; Nino Gogokhia; Laurent Managadze; Archil Chkhotua
Journal:  Int Urol Nephrol       Date:  2008-03-04       Impact factor: 2.370

Review 8.  Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis.

Authors:  Cory Abate-Shen; Michael M Shen; Edward Gelmann
Journal:  Differentiation       Date:  2008-06-28       Impact factor: 3.880

9.  Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer.

Authors:  Panagiotis J Vlachostergios; Foteini Karasavvidou; Grigorios Kakkas; Kassiani Kapatou; Ioannis Gioulbasanis; Danai D Daliani; George Moutzouris; Christos N Papandreou
Journal:  J Negat Results Biomed       Date:  2012-01-05

10.  Using molecular markers to help predict who will fail after radical prostatectomy.

Authors:  Gregory P Swanson; David Quinn
Journal:  Prostate Cancer       Date:  2011-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.